The FDA has approved DCCR (Diazoxide Choline Controlled-Release) for the treatment of hyperphagia in individuals with Prader-Willi Syndrome (PWS)! This is the first approved medication… Read More »DCCR Approval in the USA

Recent evidence from FPWR-supported studies shows that Vagus Nerve Stimulation (VNS) may reduce temper outbursts and other disruptive behaviours in individuals with PWS.

Six drugs (not including Soleno’s DCCR which has progressed past phase 3) are either moving into a phase two or phase three trial. This also… Read More »Six Drug Trials at Phase Two or Phase Three

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Harmony Biosciences’ pitolisant to treat daytime sleepiness in people with Prader-Willi syndrome… Read More »Pitolisant earns FDA orphan drug status ahead of Phase 3 trial

Soleno Therapeutics revealed positive outcomes from the randomized withdrawal phase of an extended treatment study of DCCR (Diazoxide Choline) tablets. DCCR’s primary purpose is to… Read More »DCCR Reports Positive Results

“This analysis has the potential to identify new targets for therapeutic intervention in PWS and potentially other forms of hyperphagic obesity” – The FPWR UK… Read More »2022 funding project – Genetic Determinants of Behavioural, Physical and Physiological Characteristics of PWS